Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rituximab Maintenance After Autologous Transplantation

Phase 3

Terminated

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Rituximab

First Posted Date: 2010-04-14

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01103388

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Phase 1

Withdrawn

Conditions: Chronic Myeloproliferative Disorders
Infection
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Edetate Calcium Disodium
Other: Hypertonic Saline
Drug: Ethanol
Drug: Trimethoprim-sulfamethoxazole

First Posted Date: 2010-04-12

Last Posted Date: 2013-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01101412

Simultaneous Integrated Boost (SIB) in Esophageal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer

Interventions: Radiation: Radiation Therapy

First Posted Date: 2010-04-12

Last Posted Date: 2020-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT01102088

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Not Applicable

Completed

Conditions: Leukemia

Interventions: Drug: Procrit (epoetin alfa)

First Posted Date: 2010-04-06

Last Posted Date: 2012-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 109

Registration Number: NCT01099202

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Smoking Cessation Treatment for Head & Neck Cancer Patients

Early Phase 1

Active, not recruiting

Conditions: Smoking Cessation
Head and Neck Cancer

Interventions: Behavioral: Acceptance and Commitment Therapy
Behavioral: Motivational and Behavioral Counseling
Drug: Varenicline

First Posted Date: 2010-04-05

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT01098955

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Transitional Cell Carcinoma
FIGO Stage III Ovarian Cancer
FIGO Stage IIIA1 Ovarian Cancer
FIGO Stage IVB Ovarian Cancer
Ovarian Serous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
FIGO Stage IIIA1(i) Ovarian Cancer
FIGO Stage IIIA1(ii) Ovarian Cancer
FIGO Stage IIIC Ovarian Cancer
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-04-02

Last Posted Date: 2022-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01097746

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

and more 2 locations

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Bendamustine
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2010-03-31

Last Posted Date: 2019-09-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT01096992

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fluorescent Dyes for Lymph Node Mapping

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Indocyanine green (ICG)

First Posted Date: 2010-03-30

Last Posted Date: 2015-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01095913

Locations: 🇺🇸
University of Texas Health Science Center - Houston, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Nelarabine

First Posted Date: 2010-03-29

Last Posted Date: 2020-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT01094860

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Late Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Gleevec

First Posted Date: 2010-03-25

Last Posted Date: 2016-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01092741

Locations: 🇺🇸
The University Of MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy